Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/23 cls
3SBio (SSRX) Pacific Growth Y. Katherine Xu New Buy 9% $11.85
Xu's rating reflects SSRX's position as the erythropoietin (EPO) market leader in China. She thinks sales of EPIAO to treat anemia associated with kidney diseases, red cell mobilization and chemotherapy-induced anemia as well as sales of TPIAO to treat chemotherapy-induced thrombocytopenia could grow to $56M

Read the full 696 word article

How to gain access

Continue reading with a
two-week free trial.